A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)

Organon

Status and phase

Completed

Phase 3

Conditions

Allergic Rhinitis

Treatments

Drug: Placebo

Drug: Montelukast 10 mg/loratadine 10 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01673620

0476A-484

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of montelukast 10 mg/loratadine 10 mg versus placebo in Mexican participants with allergic rhinitis.

Enrollment

69 patients

Sex

All

Ages

15 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Not pregnant or breastfeeding and does not plan to become pregnant during the study and the 14-day follow-up period
Female participants of reproductive potential agree to remain abstinent or use one acceptable method of birth control at least 14 days prior to signing the informed consent until 14 days following the last visit
History for at least 2 years of seasonal allergic rhinitis symptoms that are known to flare during the local allergy season or a clinical history of at least 2 years of perennial allergic rhinitis symptoms that persist year round
For participants with seasonal allergic rhinitis: a positive skin-prick test (wheal >= 3 mm greater than saline control) to one of the allergens active during the local allergy season or a positive radioallergosorbent test (RAST [defined as a score >= Class III])
For participants with perennial allergic rhinitis: a positive skin test (wheal >=3 mm greater than saline control) to one of the relevant perennial allergens or a positive RAST (defined as a score >= Class III)
Nonsmoker and has been a nonsmoker for at least 1 year prior to study Visit 1 with a smoking history of no more than 10 pack-years (1 pack [20 cigarettes] per day for 10 years)
Must be in good and stable physical health and mental health

Exclusion criteria

Hospitalization or hospitalization within 4 weeks of the first scheduled study visit
Pregnancy or within <= 8 weeks postpartum or is breast feeding
Any major surgical procedure within 4 weeks of the first scheduled study vist
Current or recent past abuser of alcohol or illicit drugs
Prior participation in a clinical trial of montelukast or loratadine within the 4 weeks prior to the first scheduled study visit
Requires treatment other than inhaled short-acting β-agonist for asthma

(e.g., inhaled or oral corticosteroid, theophylline, nedocromil, cromolyn, oral or long-acting inhaled β-agonist, leukotriene receptor antagonist, leukotriene synthesis inhibitor) and/or uses more than 8 puffs per day of inhaled short-acting β-agonist
Presence of an upper respiratory tract infection (URI), sinusitis, infectious rhinitis (with symptoms such as sore throat, fever, thick purulent rhinorrhea), ocular infection, or history of any of these within 4 weeks prior to the first scheduled study visit or any time between study Visits 1 and 2
Other than asthma, any active, acute, or chronic pulmonary disorder which is documented by history or physical examination
Rhinitis medicamentosa, or non-allergic rhinitis
Recent history (within 3 months prior to the first scheduled study visit) of a clinically significant psychiatric disorder
History of an anaphylactic reaction to or is otherwise hypersensitive to

montelukast, loratadine, or one of their components

History or current evidence of any general medical condition, concomitant therapy, lab abnormality or other circumstance that might confound the results of the study or interfere with the patient's participation for the full duration of the study
History of illness that would require treatment with an excluded medication, could be immediately life threatening (ventricular arrhythmia, diabetes mellitus that is not well controlled), would pose restriction on participation or successful completion of the study, or would pose additional risk to the patient by administering the study drug
History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer